Target ALS / NYGC Genetic Data Request Form

**Please send completed form to** [**cgnd\_help@nygenome.org**](mailto:cgnd_help@nygenome.org)

***\* Denotes required information***

**\*Date:**

**\*PI:**

**\*Institution:**

**\*Technical Point of Contact Name/Email:**

**\*Destination:**  RSYNC  Globus  Cloud  SFTP

Please provide technical details for data transfer destination (server path and credentials):

**\*Address**:

**\*Telephone:** **Fax**: \***Email:**

**\*What type of data files are you requesting?**

**WGS -total size of data set ~ 40TB**

VCF  GVCF  FASTQ  CRAM  SV  Expansion Hunter(if applicable)

* See ***NYGC WGS QC*** for details on sample preparation, analysis, and QC.
* VCF and GVCF files are available for download for 25 days post delivery. After 25 days these files can be pushed upon request.
* FASTQ, CRAM and SV are pushed upon request.

**RNAseq -total size of data set ~21TB**

BAM  FASTQ

* See ***NYGC RNASeq QC*** for details on sample preparation, analysis, and QC**.**
* **RNAseq Data** **availability** FASTQ and BAM files are pushed upon request.

**\*Planned use of data.**

Please provide a brief explanation (a couple sentences) of how you are planning to use this data.

Please note that the genetic data is linked to the corresponding frozen and fixed tissue samples in our Multicenter Postmortem Tissue Core. These tissue samples are available for further studies informed by the genetic data. If you are interested in acquiring these corresponding samples, please fill out the Sample Request form on the Target ALS Website.

**We require the following:**

1. “**The Target ALS Human Postmortem Tissue Core, New York Genome Center for Genomics of Neurodegenerative Disease, the Amyotrophic Lateral Sclerosis Association and the Tow Foundation**” must be acknowledged in any publications or meeting abstracts/presentations.
2. **You must provide a summary statement to Target ALS within 6 months of receiving the genetic data, detailing whether this data was used for any (1) publications, (2) meeting abstracts/talks, (3) preliminary data for grant/fellowship/other award applications.**

*We do not want your actual data/analysis. However, this information about usage is vital to help us continue to demonstrate that this effort is beneficial to the ALS research community.*

1. *Co-authorship inclusion on publications is not required, but is encouraged if any PI’s directly assist in assay development, analysis, or other aspects of a given project.*

**Any questions about the data available or the request process should be directed to:** [cgnd\_help@nygenome.org](mailto:cgnd_help@nygenome.org)